MedTrace Logo

Risperidone in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma

NCT00208182 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2006-03-10

No results posted yet for this study

Summary

This medical study is an assessment of clinical response in women with Posttraumatic Stress Disorder (PTSD) due to domestic violence or rape trauma when treated with risperidone. Response to risperidone or placebo (inactive drug) is measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8). Second, the effect of risperidone on depressive and anxiety symptoms will be assessed using the Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression and the Clinical Global Impression.

Conditions

  • Post-Traumatic Stress Disorder

Interventions

DRUG

Risperidone

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Creighton University

    lead OTHER

Principal Investigators

  • Frederick Petty, MD, PhD · Creighton University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-07-31
Completion
2004-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00208182 on ClinicalTrials.gov